Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Soluble Syndecan-1: Does This Biomarker Address a Seemingly Insoluble Problem in Inflammatory Bowel Disease?

Patterson AM.

Dig Dis Sci. 2015 Aug;60(8):2222-4. doi: 10.1007/s10620-015-3669-x. Epub 2015 Apr 25. No abstract available.

PMID:
25911586
2.

Soluble Syndecan-1 Levels Are Elevated in Patients with Inflammatory Bowel Disease.

Yablecovitch D, Stein A, Shabat-Simon M, Naftali T, Gabay G, Laish I, Oren A, Konikoff FM.

Dig Dis Sci. 2015 Aug;60(8):2419-26. doi: 10.1007/s10620-015-3589-9. Epub 2015 Feb 22.

PMID:
25702042
3.

Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies.

Mundt F, Heidari-Hamedani G, Nilsonne G, Metintas M, Hjerpe A, Dobra K.

Biomed Res Int. 2014;2014:419853. doi: 10.1155/2014/419853. Epub 2014 Jul 24.

4.

Soluble Syndecan-1: A Novel Biomarker of Small Bowel Mucosal Damage in Children with Celiac Disease.

Yablecovitch D, Oren A, Ben-Horin S, Fudim E, Eliakim R, Saker T, Konikoff FM, Kopylov U, Matthias T, Lerner A.

Dig Dis Sci. 2017 Mar;62(3):755-760. doi: 10.1007/s10620-016-4415-8. Epub 2016 Dec 26.

PMID:
28025744
5.

[Relative study of soluble syndecan-1 and prognosis of patients with multiple myeloma].

Li X, Zhang X, Lu Z, Klein B.

Zhonghua Xue Ye Xue Za Zhi. 2001 Jun;22(6):303-5. Chinese.

PMID:
11877089
6.

Could Circulatory Syndecan-1 Be a Predictable Biomarker for Acute Kidney Injury in Patients With Acute Decompensated Heart Failure?

Sueta D, Hokimoto S.

Circ J. 2015;79(7):1444-5. doi: 10.1253/circj.CJ-15-0552. Epub 2015 Jun 1. No abstract available.

7.

Serum level of circulating syndecan-1: A possible association with proliferative vasculopathy in systemic sclerosis.

Wu CY, Asano Y, Taniguchi T, Sato S, Yu HS.

J Dermatol. 2016 Jan;43(1):63-6. doi: 10.1111/1346-8138.12986. Epub 2015 Jun 16.

PMID:
26076711
8.

Elevated Syndecan-1 levels in the sera of patients with breast cancer correlate with tumor size.

Malek-Hosseini Z, Jelodar S, Talei A, Ghaderi A, Doroudchi M.

Breast Cancer. 2017 Nov;24(6):742-747. doi: 10.1007/s12282-017-0773-0. Epub 2017 Apr 5.

PMID:
28382590
9.

Evaluation of maternal serum hypoxia inducible factor-1α, progranulin and syndecan-1 levels in pregnancies with early- and late-onset preeclampsia.

Alici Davutoğlu E, Akkaya Firat A, Ozel A, Yılmaz N, Uzun I, Temel Yuksel I, Madazlı R.

J Matern Fetal Neonatal Med. 2018 Aug;31(15):1976-1982. doi: 10.1080/14767058.2017.1333098. Epub 2017 Jun 2.

PMID:
28574293
10.

Syndecan-1: A Quantitative Marker for the Endotheliopathy of Trauma.

Gonzalez Rodriguez E, Ostrowski SR, Cardenas JC, Baer LA, Tomasek JS, Henriksen HH, Stensballe J, Cotton BA, Holcomb JB, Johansson PI, Wade CE.

J Am Coll Surg. 2017 Sep;225(3):419-427. doi: 10.1016/j.jamcollsurg.2017.05.012. Epub 2017 Jun 1.

11.

Syndecan-1 improves severe acute kidney injury prediction after pediatric cardiac surgery.

de Melo Bezerra Cavalcante CT, Castelo Branco KM, Pinto Júnior VC, Meneses GC, de Oliveira Neves FM, de Souza NM, Penaforte KL, Martins AM, Libório AB.

J Thorac Cardiovasc Surg. 2016 Jul;152(1):178-186.e2. doi: 10.1016/j.jtcvs.2016.03.079.

12.

Syndecan-1 plasma levels during coronary artery bypass surgery with and without cardiopulmonary bypass.

Svennevig K, Hoel T, Thiara A, Kolset S, Castelheim A, Mollnes T, Brosstad F, Fosse E, Svennevig J.

Perfusion. 2008 May;23(3):165-71. doi: 10.1177/0267659108098215.

PMID:
19029267
13.

Endothelial Glycocalyx as Biomarker for Cardiovascular Diseases: Mechanistic and Clinical Implications.

Kim YH, Nijst P, Kiefer K, Tang WH.

Curr Heart Fail Rep. 2017 Apr;14(2):117-126. doi: 10.1007/s11897-017-0320-5. Review.

14.

Reduced serum levels of syndecan-1 in patients with tongue squamous cell carcinoma.

Shegefti MS, Malekzadeh M, Malek-Hosseini Z, Khademi B, Ghaderi A, Doroudchi M.

Laryngoscope. 2016 May;126(5):E191-5. doi: 10.1002/lary.25812. Epub 2015 Dec 15.

PMID:
26667395
15.

Low molecular weight heparin relieves experimental colitis in mice by downregulating IL-1β and inhibiting syndecan-1 shedding in the intestinal mucosa.

Wang XF, Li AM, Li J, Lin SY, Chen CD, Zhou YL, Wang X, Chen CL, Liu SD, Chen Y.

PLoS One. 2013 Jul 18;8(7):e66397. doi: 10.1371/journal.pone.0066397. Print 2013.

16.

Endothelial Glycocalyx Damage and Renal Dysfunction in HIV Patients Receiving Combined Antiretroviral Therapy.

Meneses GC, Cavalcante MG, da Silva Junior GB, Martins AMC, Neto RDJP, Libório AB, De Francesco Daher E.

AIDS Res Hum Retroviruses. 2017 Jul;33(7):703-710. doi: 10.1089/AID.2016.0284. Epub 2017 Apr 18.

PMID:
28260391
17.

Circulating syndecan-1 predicts the development of disseminated intravascular coagulation in patients with sepsis.

Ikeda M, Matsumoto H, Ogura H, Hirose T, Shimizu K, Yamamoto K, Maruyama I, Shimazu T.

J Crit Care. 2018 Feb;43:48-53. doi: 10.1016/j.jcrc.2017.07.049. Epub 2017 Jul 28.

PMID:
28843664
18.

Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study.

Vradelis S, Kouklakis G.

Scand J Gastroenterol. 2014 Nov;49(11):1397. doi: 10.3109/00365521.2014.959041. Epub 2014 Sep 17. No abstract available.

PMID:
25228025
19.

Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score.

Jary M, Lecomte T, Bouché O, Kim S, Dobi E, Queiroz L, Ghiringhelli F, Etienne H, Léger J, Godet Y, Balland J, Lakkis Z, Adotevi O, Bonnetain F, Borg C, Vernerey D.

Int J Cancer. 2016 Nov 15;139(10):2325-35. doi: 10.1002/ijc.30367. Epub 2016 Aug 13.

20.

Increased syndecan-1 in serum is related to early nephropathy in type 1 diabetes mellitus patients.

Svennevig K, Kolset SO, Bangstad HJ.

Diabetologia. 2006 Sep;49(9):2214-6. Epub 2006 Jul 11. No abstract available. Erratum in: Diabetologia. 2006 Dec;49(12):3100. Dosage error in article text.

PMID:
16832664

Supplemental Content

Support Center